BioCryst Pharmaceuticals | BCRX - Ebit


BioCryst Pharmaceuticals reported $98.46M in EBIT for its fiscal quarter ending in June of 2026.





Ebit Change Date
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Chugai Pharma JPY 202.95B 42.09B Sep/2026
Daiichi Sankyo JPY 108.7B 23.6B Sep/2026
DBV Technologies USD -64.8M 16.9M Sep/2026
Enanta Pharmaceuticals USD -23.54M 6.31M Dec/2024
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Glaxosmithkline GBP 2.15B 157M Sep/2026
Incyte USD -707.47M 1.41B Sep/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Novavax USD 20.94M 100.32M Dec/2025
PTC Therapeutics USD 146.03M 100.14M Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026